No Data
Unveiling 6 Analyst Insights On United Therapeutics
United Therapeutics (NASDAQ:UTHR) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below offers a condensed view of their rece
United Therapeutics Is Maintained at Buy by UBS
United Therapeutics Is Maintained at Buy by UBS
UBS Maintains Buy on United Therapeutics, Raises Price Target to $370
UBS analyst Ashwani Verma maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $300 to $370.
United Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 16.91% UBS $300 → $370 Maintains Buy 06/12/2024 10.6% Wells Fargo $325 → $350 Maintains Overwei
UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating
United Therapeutics (UTHR) has an average outperform rating and a price target range of $221 to $400, according to analysts polled by Capital IQ.
Express News | United Therapeutics Corp : UBS Raises Target Price to $370 From $300